DalCor completes $150m financing to continue development of dalcetrapib in ACS
DalCor Pharmaceuticals has wrapped up a private financing round valued at $150m to continue the development of dalcetrapib in genetically distinct patients with acute coronary syndrome (ACS). The proceeds will be used to fund a phase 3 clinical trial of dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, in patients who have recently experienced ACS.DalCor plans to start the trial this month at the Montreal Heart Institute. It will target 5,000 patients.
Click on this link for more information.